Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL

Blood

Volumn 117, Issue 3, 2011, Pages 862-871

  Chen, Shih Shih ^a,b,c   Claus, Rainer ^d   Lucas, David M ^b,c   Yu, Lianbo ^b   Qian, Jiang ^c   Ruppert, Amy S ^b   West, Derek A ^c   Williams, Katie E ^c   Johnson, Amy J ^c   Sablitzky, Fred ^e   Plass, Christoph ^d   Byrd, John C ^b,c,f  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^f B302 Starling Loving Hall   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; DEXAMETHASONE; INHIBITOR OF DIFFERENTIATION 1; INHIBITOR OF DIFFERENTIATION 2; INHIBITOR OF DIFFERENTIATION 3; INHIBITOR OF DIFFERENTIATION 4; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CELL STRAIN HEK293; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA BINDING; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNIVARIATE ANALYSIS;

EID: 78751682784     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-05-284638     Document Type: Article

References (43)

1. Chim C, Wong K, Qi Y, et al. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis. 2010;31:745-750.
2. Chiorazzi N. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol. 2007;20(3):399-413. (Pubitemid 47250501)
3. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115(3):755-764. (Pubitemid 40322252)
4. Pekarsky Y, Zanesi N, Aqeilan RI, Croce CM. Animal models for chronic lymphocytic leukemia. J Cell Biochem. 2007;100(5):1109-1118. (Pubitemid 46480394)
5. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U SA. 2002;99(10):6955-6960. (Pubitemid 34526239)
6. Yan XJ, Albesiano E, Zanesi N, et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2006;103(31):11713-11718. (Pubitemid 44182516)
7. Pekarsky Y, Calin GA, Aqeilan R. Chronic lymphocytic leukemia: molecular genetics and animal models. Curr Top Microbiol Immunol. 2005;294:51-70. (Pubitemid 41491250)
8. Johnson AJ, Lucas DM, Muthusamy N, et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood. 2006;108(4):1334-1338. (Pubitemid 44232033)
9. Chen SS, Raval A, Johnson AJ, et al. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2009;106(32):13433-13438.
10. Chen SS, Sherman MH, Hertlein E, et al. Epigenetic alterations in a murine model for chronic lymphocytic leukemia. Cell Cycle. 2009;8(22):3663-3667.
11. Norton JD, Deed RW, Craggs G, Sablitzky F. Id helix-loop-helix proteins in cell growth and diffeerentiation. Trends Cell Biol. 1998;8(2):58-65. (Pubitemid 28056812)
12. Gómez Del Pulgar T, Valdes-Mora F, Bandres E, et al. Cdc42 is highly expressed in colorectal adenocarcinoma and down-regulates ID4 through an epigenetic mechanism. Int J Oncol. 2008;33(1):185-193.
13. Carey JP, Asirvatham AJ, Galm O, Ghogomu TA, Chaudhary J. Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer. BMC Cancer. 2009;9:173.
14. Asirvatham AJ, Schmidt MA, Chaudhary J. Non-redundant inhibitor of differentiation (Id) gene expression and function in human prostate epithelial cells. Prostate. 2006;66(9):921-935. (Pubitemid 43849591)
15. Chan TC, Jiang J, Temenak JJ, Richards AL. Development of a rapid method for determining the infectious dose (ID)50 of Orientia tsutsugamushi in a scrub typhus mouse model for the evaluation of vaccine candidates. Vaccine. 2003;21(31):4550-4554. (Pubitemid 37315775)
16. Welcsh PL, Lee MK, Gonzalez-Hernandez RM, et al. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci U S A. 2002;99(11):7560-7565. (Pubitemid 34568730)
17. Wu Q, Hoffmann MJ, Hartmann FH, Schulz WA. Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer. Mol Cancer. 2005;4(1):16. (Pubitemid 41460843)
18. Beger C, Pierce LN, Kruger M, et al. Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc Natl Acad Sci U S A. 2001;98(1):130-135. (Pubitemid 32095875)
19. Yu L, Liu C, Vandeusen J, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet. 2005;37(3):265-274. (Pubitemid 41716253)
20. Raval A, Tanner SM, Byrd JC, et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell. 2007;129(5):879-890. (Pubitemid 46813150)
21. Bedford L, Walker R, Kondo T, van Cruchten I, King ER, Sablitzky F. Id4 is required for the correct timing of neural differentiation. Dev Biol. 2005;280(2):386-395. (Pubitemid 40692139)
22. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997. (Pubitemid 26189840)
23. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression- free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105(1):49-53. (Pubitemid 40053062)
24. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101(1):6-14.
25. Costello JF, Plass C, Cavenee WK. Restriction landmark genome scanning. Methods Mol Biol. 2002;200:53-70.
26. Ehrich M, Nelson MR, Stanssens P, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A. 2005;102(44):15785-15790. (Pubitemid 41552820)
27. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003;34(2):374-378. (Pubitemid 36184095)
28. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-264.
29. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
30. Gordon D, Haynes C, Yang Y, Kramer PL, Finch SJ. Linear trend tests for case-control genetic association that incorporate random phenotype and genotype misclassification error. Genet Epidemiol. 2007;31(8):853-870.
31. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol. 2003;4(10):R70.
32. Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood. 2002;100(2):635-639.
33. Rawstron AC, Bennett FL, O'Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008;359(6):575-583.
34. Marti GE, Rawstron AC, Ghia P, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005;130(3):325-332. (Pubitemid 43899581)
35. Enzler T, Kater AP, Zhang W, et al. Chronic lymphocytic leukemia of E{micro}-TCL1 transgenic mice undergoes rapid cell-turnover that can be offset by extrinsic CD257 to accelerate disease progression [Erratum in: Blood. 2010;29;116(4):671]. Blood. 2009;114(20):4469-4476.
36. Noetzel E, Veeck J, Niederacher D, et al. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer. 2008;8:154. (Pubitemid 351917269)
37. Umetani N, Mori T, Koyanagi K, et al. Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene. 2005;24(29):4721-4727. (Pubitemid 41032608)
38. Wang H, Wang XQ, Xu XP, Lin GW. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome. Leuk Res. 2010;34(5):598-604.
39. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell. 1993;72(2):233-245. (Pubitemid 23044938)
40. Dai P, Xiong WC, Mei L. Erbin inhibits RAF activation by disrupting the sur-8-Ras-Raf complex. J Biol Chem. 2006;281(2):927-933.
41. Nuckel H, Huttmann A, Klein-Hitpass L, et al. Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2006;47(6):1053-1061. (Pubitemid 44102969)
42. van't Veer MB, Brooijmans AM, Langerak AW, et al. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica. 2006;91(1):56-63.
43. Garrido C, Schmitt E, Cande C, Vahsen N, Parcellier A, Kroemer G. HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle. 2003;2(6):579-584.